Immuneering Corporation Class A

Stage 4 · Declining · week 5

As of Oct 22, 2026, Immuneering is in Stage 4, the downtrend phase, now in week 5 (since Sep 23, 2026). It closed at $3.81, 54.3% below its 52-week high and below its 200-day average, which is falling.

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. More about the company

$3.81

+1.87% today

$246M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is IMRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 32w

S2 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 3w → S3 6w → S4 10w → S1 6w → S4 32w → S1 10w → S2 2w → S3 6w → S2 4w → S3 6w → S4 10w → S1 4w → S2 21w → S3 5w → S2 1w → S3 8w → S4 5w → S1 7w → S4 12w → S1 4w → S4 4w current

Total tracked: 164 weeks across 21 stage runs.

IMRX among Biotechnology299th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…299	IMRXImmuneering Corporation Class A	Stage 4 · wk 5	31	−13.0%

vs 52W High

-54.3%

$3.42 lo$8.33 hi

54.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-21.4%

200 DMA: $4.85 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.76x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.0%

-11.8%

-37.8%

YTD

-42.4%

-34.9%

Scan Membership

Breakout Watch

Latest: 2025-01-21

5 appearances in last 60 days. First seen: 2022-10-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 0.76x

2026-10-21S4

Wk 5 · Vol 0.61x

2026-10-20S4

Wk 4 · Vol 1.32x

2026-10-19S4

Wk 4 · Vol 0.60x

2026-10-16S4

Wk 4 · Vol 1.05x

2026-10-15S4

Wk 4 · Vol 1.33x

2026-10-14S4

Wk 4 · Vol 1.15x

2026-10-13S4

Wk 3 · Vol 1.06x

2026-10-12S4

Wk 3 · Vol 0.76x

2026-10-09S4

Wk 3 · Vol 1.03x

2026-10-08S4

Wk 3 · Vol 2.88x

2026-10-07S4

Wk 3 · Vol 1.12x

Moving averages & range

50 DMA

$4.44

200 DMA

$4.85

52W High

$8.33

52W Low

$3.42

5D Low

$3.59

Resistance levels (recent highs)

20d High

$4.27

60d High

$5.33

120d High

$5.77

250d High

$8.33

Next resistance

+12.1%

to 20d High

ROE

-52.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.3

Immuneering: quick answers

What stage is Immuneering in?

As of Oct 22, 2026, Immuneering (IMRX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 23, 2026 and is in week 5. What the four stages mean

Is Immuneering in an uptrend?

No. Immuneering is in a Stage 4 downtrend. It trades 21.4% below its 200-day average, which is falling.

How far is Immuneering from its 52-week high?

Immuneering closed at $3.81 on Oct 22, 2026, 54.3% below its 52-week high of $8.33. Its 52-week low is $3.42.

How has Immuneering performed over the past year?

As of Oct 22, 2026, Immuneering is down 34.9% over the past year and down 42.4% so far in 2026.

Which sector and industry is Immuneering in?

Immuneering is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.